Vision Pharma Seeks $3M From Sunrise For Adulterated Drugs

Law360, New York (August 6, 2013, 7:09 PM EDT) -- Vision Pharma LLC on Monday filed suit against Sunrise Pharmaceutical Inc. in New Jersey federal court, accusing the company of breaching a $3 million contract by producing adulterated generic drugs that were later deemed unsellable by the U.S. Food & Drug Administration.

According to the August 5th complaint, Vision, an Estero, Fla.-based generic pharmaceutical company, entered a series of supply agreements with Sunrise of Rahway, N.J., to produce generic forms of medications for gout and gastrointestinal problems.

Under the terms of the contract, Sunrise was expressly...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.